Skip to main content

Latest Market News — Page 185

Page 185 · 30 stories scored 7+ · newest 7:22 AM ET · How scores work

Thu, Aug 630 stories
9HWMHowmet Aerospace Inc.Howmet Aerospace Q2 Revenue Jumps 24%, Raises 2026 Guidance Across the BoardEarnings & guidance · Reuters▲ PositivePro7SRRKScholar Rock Holding CorpScholar Rock Narrows Q2 Loss, Eyes FDA Nod for Apitegromab by Sept 30Earnings & guidance · Reuters▲ Positive8KDPKeurig Dr Pepper Inc.Keurig Dr Pepper Q2 Revenue Beats, EPS Tops Estimates; Guidance ReaffirmedEarnings & guidance · Reuters▲ PositivePro9INSMINSMED IncInsmed Q2 Revenue Soars 49% on BRINSUPRI Launch, Guidance RaisedEarnings & guidance · Reuters▲ PositivePro7LCUTLIFETIME BRANDS, INCLifetime Brands Lifts FY25 Profit Outlook, Shares Poised to ReactEarnings & guidance · Dow Jones Newswires▲ Positive7VRDNViridian Therapeutics, Inc.Viridian Posts $69.72/Share Q1 Loss, Deepening Cash BurnEarnings & guidance · Dow Jones Newswires▼ Negative8IRWDIRONWOOD PHARMACEUTICALS INCIronwood Lifts 2026 Outlook, Signaling Stronger GrowthEarnings & guidance · Dow Jones Newswires▲ PositivePro8ZTSZoetis Inc.Zoetis Issues 2026 Adj EPS Guidance of $6.15-$6.25Earnings & guidance · Dow Jones Newswires● NeutralPro7LNTHLantheus Holdings, Inc.Lantheus Q2 Beats Across the Board, But Suspends Guidance Amid $8B Curium BuyoutEarnings & guidance · Reuters▲ Positive8PENNPENN Entertainment, Inc.PENN Q2 Revenue Meets Estimates, But EBITDA Misses by $143MEarnings & guidance · Reuters▼ NegativePro9FLNCFluence Energy, Inc.Fluence Misses Q3 Estimates, Slashes FY2026 Guidance on Production DelaysEarnings & guidance · Benzinga▼ NegativePro8VSNTVersant Media Group, Inc.Versant Media Lifts 2026 Outlook After Q2 Earnings Beat, Digital MomentumEarnings & guidance · Binance News▲ PositivePro9TARSTarsus Pharmaceuticals, Inc.Tarsus Q2 XDEMVY Sales Surge 69% to $174M, Raises 2026 Guidance to $705M, Acquires AlkeusEarnings & guidance · GlobeNewswire▲ PositivePro8OCGNOcugen, Inc.Ocugen's OCU410 Gets FDA Nod for Phase 3, RMAT Designation; Cash Runway Extended to 2028Product & regulatory · GlobeNewswire▲ PositivePro8IOVAIOVANCE BIOTHERAPEUTICS, INC.Iovance Posts Record $99M Q2 Revenue, 56% Gross Margin; FDA Grants Fast Track for SarcomaEarnings & guidance · GlobeNewswire▲ PositivePro7SPAISafe Pro Group Inc.$780K DoW Order for AI Threat Mapping and Blue UAS DronesM&A & partnerships · GlobeNewswire▲ Positive7ETHAiShares Ethereum Trust ETFBlackRock's Ethereum ETF Plans 1-for-3 Reverse Split After 40% Price DropGovernance · CryptoProwl● Neutral8TGLSTecnoglass Holdings Inc.Record Q2 Revenue of $295.3M, Backlog Hits $1.38B, Guidance UpdatedEarnings & guidance · GlobeNewswire● NeutralPro8ROIVRoivant Sciences Ltd.Roivant Posts $3.9B Cash, $209M Buyback, and Genevant's $950M Moderna WindfallEarnings & guidance · GlobeNewswire▲ PositivePro7GENBGenerate Biomedicines, Inc.Generate Biomedicines Reports Q2 Cash of $457M, Advances Phase 3 Asthma TrialsEarnings & guidance · GlobeNewswire● Neutral8GLUEMonte Rosa Therapeutics, Inc.Monte Rosa Reports $626M Cash, Advances Three Phase 2 TrialsEarnings & guidance · GlobeNewswire▲ PositivePro7CLYMClimb Bio, Inc.Climb Bio Extends Cash Runway to 2028, Sets Key Data Catalysts for H2 2026Earnings & guidance · GlobeNewswire▲ Positive7CGEMCullinan Therapeutics, Inc.Cullinan Reports $356M Cash, Runway Into 2029; Key Data Readouts AheadEarnings & guidance · GlobeNewswire▲ Positive8HROWHARROW, INC.Harrow Acquires TYRVAYA, First FDA-Approved Nasal Spray for Dry Eye, for Up to $100MM&A & partnerships · GlobeNewswire▲ PositivePro7NTLAIntellia Therapeutics, Inc.Intellia's Q2 Results Highlight Positive Phase 3 Data and FDA Filing Plans for Gene-Editing TherapyEarnings & guidance · GlobeNewswire▲ Positive8SHCSotera Health CoSotera Health Raises FY 2026 Outlook After Strong Q2, Hits Leverage TargetEarnings & guidance · GlobeNewswire▲ PositivePro7AVTXAvalo Therapeutics, Inc.Avalo Posts $36.4M Q2 Loss, Cash at $472M; Phase 3 for Abdakibart in HS Set for H1 2027Earnings & guidance · GlobeNewswire● Neutral8IRDOpus Genetics, Inc.Opus Genetics Q2 Cash at $88.8M, BEST1 Data Due September; Five Gene Therapies AdvancingEarnings & guidance · GlobeNewswire▲ PositivePro7RNACCartesian Therapeutics, Inc.Cartesian Therapeutics Reports Q2 Results, Cash Runway Into 2028, and Four Clinical Readouts in Next 12 MonthsEarnings & guidance · GlobeNewswire● Neutral8PZZAPAPA JOHNS INTERNATIONAL INCPapa John's Q2 Adj EPS $0.46 Beats Estimates, Revenue Tops $507MEarnings & guidance · Dow Jones Newswires▲ PositivePro
How Wiseek picks and scores these

How Wiseek curates this list

Every entry started life as licensed wire-service reporting (Reuters, Dow Jones Newswires, and similar publishers) covering ticker-attributable events. Wiseek's editorial pipeline ingests these in real time, runs each headline through our domain-tuned importance scorer, and surfaces only items rated 7 or higher on a 1–10 market-impact scale. Items below 7 are filtered out at the database query so the public feed stays signal-dense.

What "AI-ranked analysis" means

For each item we publish a plain-English summary, a sentiment label (positive / negative / neutral), and a structured list of key events extracted from the underlying source. Score, summary, and sentiment come from Wiseek's in-house models — not generic chatbot output. See our methodology for the full pipeline and our editorial policy for source-attribution standards.

What's not on this page

Generic market commentary, opinion columns, low-impact press releases, and items below the 7-point importance threshold. Wiseek aggregates and scores wire-service headlines; the underlying publishers retain their original reporting and are credited per article.

Track by company

Follow SEC filings and market news for a specific company by visiting its ticker page: AAPL, MSFT, NVDA, TSLA, AMZN, GOOGL, META, JPM, V, UNH, XOM, AVGO, LLY, MA, COST, JNJ, PG, HD, ABBV, MRK, KO, NFLX, AMD, WMT, CVX, BAC — or browse all covered tickers.